Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP lifted its holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 492.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,735 shares of the biotechnology company’s stock after buying an additional 58,787 shares during the period. Two Sigma Advisers LP’s holdings in Adaptimmune Therapeutics were worth $38,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Invesco Ltd. raised its holdings in Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 28,526 shares during the last quarter. Virtu Financial LLC grew its position in shares of Adaptimmune Therapeutics by 21.5% in the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 21,688 shares in the last quarter. LPL Financial LLC grew its position in shares of Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 94,623 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Adaptimmune Therapeutics by 87.7% in the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 152,780 shares during the last quarter. Finally, Rock Springs Capital Management LP increased its holdings in shares of Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 58,000 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Guggenheim lowered their price objective on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research note on Wednesday, March 26th. Wells Fargo & Company reduced their price target on Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 14th. Scotiabank lowered their price target on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research report on Friday, March 21st. Jones Trading lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, April 11th. Finally, Barclays reduced their target price on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating on the stock in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Adaptimmune Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $1.52.

Adaptimmune Therapeutics Price Performance

NASDAQ:ADAP opened at $0.28 on Monday. Adaptimmune Therapeutics plc has a 52 week low of $0.20 and a 52 week high of $1.48. The stock’s fifty day moving average is $0.27 and its two-hundred day moving average is $0.45. The company has a market capitalization of $75.01 million, a P/E ratio of -1.29 and a beta of 2.24. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The firm had revenue of $7.29 million for the quarter, compared to analyst estimates of $6.55 million. Equities analysts expect that Adaptimmune Therapeutics plc will post -0.14 EPS for the current year.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.